PRevEnting FracturEs in REnal Disease - 1 (PREFERRED-1)
Denosumab for the Prevention of Fragility Fractures in Hemodialysis: a Pilot Study for an Innovative, Randomized-controlled Trial, Embedded in Routine Care
Sponsor: Academic Medical Organization of Southwestern Ontario
Listed as NCT05096195, this PHASE4 trial focuses on Chronic Kidney Disease-Mineral and Bone Disorder and Dialysis; Complications and remains ongoing. Sponsored by Academic Medical Organization of Southwestern Ontario, it has been updated 11 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Jun 2025 — Present [monthly]
Active Not Recruiting PHASE4
-
Oct 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE4
▶ Show 6 earlier versions
-
Oct 2023 — Jun 2024 [monthly]
Recruiting PHASE4
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE4
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE4
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2021 — Jun 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Academic Medical Organization of Southwestern Ontario
- ICES
- The Kidney Foundation of Canada
- Western University
- Western University, Canada
For direct contact, visit the study record on ClinicalTrials.gov .